1-4 of 4
Nobuya Ishii
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

Free
Martin H. Voss, Cinta Hierro, Rebecca S. Heist, James M. Cleary, Funda Meric-Bernstam, Josep Tabernero, Filip Janku, Leena Gandhi, A. John Iafrate, Darrell R. Borger, Nobuya Ishii, Youyou Hu, Yulia Kirpicheva, Valerie Nicolas-Metral, Anna Pokorska-Bocci, Anne Vaslin Chessex, Claudio Zanna, Keith T. Flaherty, Jose Baselga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (9): 2699–2707.
https://doi.org/10.1158/1078-0432.CCR-18-1959
Published: 01 May 2019
View article titled, A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Open the PDF for A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations in another window
Includes: Supplementary data
Journal Articles

The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations

Free
Hiroshi Tanaka, Miyuki Yoshida, Hiromi Tanimura, Toshihiko Fujii, Kiyoaki Sakata, Yukako Tachibana, Jun Ohwada, Hirosato Ebiike, Shino Kuramoto, Keiichi Morita, Yasushi Yoshimura, Toshikazu Yamazaki, Nobuya Ishii, Osamu Kondoh, Yuko Aoki
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3272–3281.
https://doi.org/10.1158/1078-0432.CCR-10-2882
Published: 15 May 2011
View article titled, The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations
Open the PDF for The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations in another window
Includes: Supplementary data
Journal Articles

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker

Free
Lucy Lee, Huifeng Niu, Ruediger Rueger, Yuriko Igawa, Jonathan Deutsch, Nobuya Ishii, Song Mu, Yuuichiro Sakamoto, Rachel Busse-Reid, Claude Gimmi, Petra Goelzer, Stefanie De Schepper, Yashushi Yoshimura, Joanne Barrett, Yuji Ishikawa, Georges Weissgerber, Richard Peck
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (23): 7368–7374.
https://doi.org/10.1158/1078-0432.CCR-09-1696
Published: 30 November 2009
View article titled, The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker
Open the PDF for The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker in another window
Journal Articles

Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells

Free
Aikou Okamoto, Takashi Nikaido, Kazunori Ochiai, Satoshi Takakura, Misato Saito, Yuko Aoki, Nobuya Ishii, Nozomu Yanaihara, Kyosuke Yamada, Osamu Takikawa, Rie Kawaguchi, Seiji Isonishi, Tadao Tanaka, Mitsuyoshi Urashima
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (16): 6030–6039.
https://doi.org/10.1158/1078-0432.CCR-04-2671
Published: 22 August 2005
View article titled, Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells
Open the PDF for Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells in another window